Aim: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII) in participants with type 1 diabetes (T1D).
| INTRODUCTION

Insulin pump therapy (or continuous subcutaneous insulin infusion
[CSII]) in people with type 1 diabetes (T1D) presents advantages over multiple daily insulin injection (MDI) regimens. These include improved glycaemic control and a reduced rate of hypoglycaemic episodes 1, 2 ; however, real-world data show that, despite using CSII with or without continuous monitoring devices, only 30% of adults with T1D achieve glycated haemoglobin (HbA1c) of <53 mmol/mol (<7.0%). 3 In addition to better insulin delivery and monitoring technologies, there is also a need to develop insulins with pharmacological and glucose-lowering profiles that more closely resemble physiological insulin action. To this end, ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), 4 BioChaperone lispro, 5 and treprostinil lispro 6 that target postprandial glucose (PPG) excursions, are under study or in development for use with MDI and CSII regimens; inhaled insulin is also under study as an alternative approach. 7 PPG is an important component of improving overall glycaemic control.
Faster aspart is conventional insulin aspart (IAsp) in a new formulation, in which two excipients, niacinamide and L-arginine, have been added. 4 In a pooled analysis in participants with T1D, faster aspart demonstrated an earlier onset of appearance, a higher early insulin exposure and a greater early glucose-lowering effect vs IAsp, when both were administered by subcutaneous injection. 4 More pronounced clinical pharmacological improvements and a greater glucose-lowering effect were demonstrated in people with T1D using CSII. 8, 9 With regard to change in HbA1c in people with T1D, faster aspart was non-inferior (0.4% margin) to mealtime IAsp when combined with insulin detemir after 26 weeks of treatment. In addition, faster aspart was associated with a significantly greater reduction in HbA1c and superior 2-hour PPG increment (meal test), with no difference in the incidence of overall severe or blood glucose (BG)-confirmed hypoglycaemia. 10 Faster aspart was compared with IAsp during CSII therapy in a randomized study of 37 participants with T1D. There were no detected microscopically confirmed infusion-set occlusions in either treatment arm over a 6-week period.
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The aim of the present onset 5 study was to confirm the effect of CSII treatment with faster aspart regarding glycaemic control by comparing it to CSII treatment with IAsp, in adults with T1D. The trial aimed to test superiority in terms of PPG regulation and time spent with low interstitial/sensor glucose levels, while also evaluating the CSII safety profile of both treatments. The trial was designed to quantify a population average effect for participants with T1D irrespective of adherence to randomized treatment and use of ancillary therapies.
The primary objective was to estimate the effect based on difference in HbA1c from baseline to 16 weeks under these circumstances.
| MATERIALS AND METHODS
| Study design
In this double-blind, randomized, multicentre, parallel-group, treat-totarget trial with a 4-week run-in and 16-week treatment period All patients provided written informed consent.
| Participants
Adults (≥18 years) with T1D (diagnosed clinically for ≥12 months)
were eligible if they were using the same insulin pump (MiniMed530G, Paradigm Veo, Paradigm Revel or Paradigm; Medtronic Inc, Minneapolis, Minnesota) for CSII therapy with a rapid-acting insulin analogue for ≥6 months prior to screening, and they were willing to stay on the same pump model throughout the trial. Further eligibility criteria were HbA1c 53 to 75 mmol/mol (7.0%-9.0%) and body mass index ≤35 kg/m 2 . Full inclusion and exclusion criteria are listed in the Supplementary Appendix within Supporting Information.
| Procedures
During the 4-week run-in period, participants remained on their pretrial insulin, and basal pump rates and bolus dose calculator settings
were not adjusted unless for safety reasons. At randomization, participants switched from pre-trial insulin to faster aspart or IAsp (both 100 U/mL), both double-blind, on a unit-for-unit basis, keeping current pump parameters the same. During the 16-week treatment period (considered sufficient to reach a stable HbA1c level), the fasting and preprandial BG glycaemic target was 4.0 to 6.0 mmol/L (71-108 mg/dL). The meal test was conducted with pre-trial insulin before randomization at week 0 and with participant's study medication at week 16.
| Continuous glucose monitoring
No more than 50% of participants were allowed to use their own realtime continuous glucose monitoring (CGM) during the trial. Participants who did not use CGM pre-trial did not start using CGM after enrolment.
Participants who were using CGM pre-trial did not change normal practice after enrolment. They were not allowed to use low glucose suspend mode if it was a pump feature. Randomization was stratified according to use of unblinded CGM. All participants were provided with a blinded CGM device to wear during three trial periods: (a) before randomization (including during the pre-treatment meal test); (b) before the 8th week after randomization; and (c) before the 16th week after randomization (including during the within-treatment meal test).
2.6 | Self-measured blood glucose
At the start of the run-in, participants were supplied with a BG meter to measure glucose values and to calibrate the blinded CGM. All SMBG values were automatically transferred to the pump. Four-point profiles were recorded daily for insulin titration purposes, and 7-7-9-point profiles were recorded on 3 consecutive days before scheduled clinic visits (and the morning of the visit) at weeks 0, 8 and 16, and were used to evaluate the glucose profile.
| Outcomes
The primary endpoint was change from baseline in HbA1c 16 weeks after randomization.
Confirmatory secondary endpoints were change from baseline Table S1 , Supporting Information.
Severe hypoglycaemia was defined according to the American Diabetes Association classification 12 and BG-confirmed hypoglycaemia was defined as a plasma glucose value <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia. Mealrelated hypoglycaemic episodes were evaluated from start of meal (0-1-hour, >1-2-hour, >2-3-hour and >3-4-hour time points).
| Statistical analysis
All statistical analyses were prespecified. Efficacy endpoints were summarized and analysed using the full analysis set, and results are presented based on data from all randomized participants for the entire trial period, which includes data collected after participants prematurely discontinued treatment. Safety endpoints (and insulin dose and pump parameters) were summarized using the safety analysis set (participants who received ≥1 dose of IAsp or faster aspart) and are presented based on data collected up to and including 7 days after discontinuation of treatment. Statistical analysis of the primary and secondary confirmatory endpoints followed a stepwise hierarchical procedure ( Figure S2 , Supporting Information). Non-inferiority (primary endpoint) was confirmed if the upper boundary of the two-sided 95% confidence interval (CI) was ≤0.4%. One-sided P values are presented for non-inferiority analyses and for the other confirmatory analyses, with two-sided P values for treatment differences presented for all other analyses.
Change from baseline in HbA1c, PPG and PPG increment (meal test) 16 weeks after randomization was analysed using a multiple imputation model. HbA1c responder endpoints were analysed using a logistic regression model. Change from baseline in mean 7-7-9-point profiles, mean PPG, mean PPG increments (7-7-9-point profiles), 1,5-AG, time spent with low IG levels, mean prandial IG increments, FPG, and body weight were analysed using a multiple imputation model similar to the model used for the primary endpoint. The number of treatment-emergent severe or BG-confirmed hypoglycaemic episodes was analysed using a negative binomial regression model.
The sample-size calculation and further details on statistical methods for the primary and secondary endpoints are provided in the Supplementary Appendix within Supporting Information.
| RESULTS
A total of 472 participants were randomized to CSII treatment with either faster aspart (n = 236) or IAsp (n = 236) between July 2016 and July 2017. All randomized participants were exposed to treatment; 463 participants (98.1%) completed the trial period, while 455 (96.4%) completed the treatment period without premature discontinuation of randomized treatment ( Figure S3 , Supporting Information). The most frequent reason for discontinuing treatment or withdrawing from the trial was "participant decision." Baseline characteristics were similar between treatment arms (Table 1) . Approximately 25% of participants in each treatment arm were using their own CGM device.
In the faster aspart and IAsp treatment arms, HbA1c decreased from 61.61 mmol/mol (7.79%) and 61.80 mmol/mol (7.80%) to 58.38 mmol/ mol (7.49%) and 58.41 mmol/mol (7.49%), respectively, during the run-in period, followed by a further change 16 weeks after randomization to 57.77 mmol/mol (7.44%) in the faster aspart arm and 56.83 mmol/mol (7.35%) in the IAsp arm ( Figure 1 ). Non-inferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was confirmed with an estimated treatment difference (ETD) of 1.0 mmol/mol (95% CI 0.14; 1.87) or 0.09% (95% CI 0.01; 0.17; P < 0.001) for non-inferiority (0.4% margin).
This difference was statistically significantly in favour of IAsp (P < 0.02).
Superiority of faster aspart to IAsp with regard to the change from baseline in HbA1c could not be confirmed; therefore, the hierarchical testing was stopped after step 3 (Table S2 , Supporting Information).
The proportion of participants achieving HbA1c target <53 mmol/mol (7.0%) is presented in Table S3 (Table S3 , Supporting Information). IG measurements during the meal test also support the PPG findings above (Table S3 , Supporting Information).
Prandial IG and IG increment profiles at baseline and week 16 are presented in Figure 3 . For breakfast, lunch, main evening meal, and across all meals, the incremental rise in mean IG after 30 minutes,
and the mean across all meals ( Figure S4 , Supporting Information). There was no statistically significant difference between treatments in the change from baseline to IG peak or time to IG peak (Table S3, Mean glycated haemoglobin (HbA1c) over time. Error bars: ± SE (mean). *Estimated treatment difference was in favour of insulin aspart: 1.00 mmol/mol (95% confidence interval [CI] 0.14; 1.87) or 0.09% (95% CI 0.01; 0.17); P = 0.022. Non-inferiority confirmed at 0.4% level (one-sided test for non-inferiority evaluated at the 2.5% level: P < 0.001). All available information regardless of treatment discontinuation was used. Faster aspart = fast-acting insulin aspart were performed had to be 4.0 to 8.8 mmol/L (71-160 mg/dL). At week 8 there was no requirement for any particular fasting SMBG value.
6.48]). The fasting SMBG levels on the days when the meal tests
Mean and median daily basal and bolus insulin doses remained stable over the treatment period in both groups (Table S4, 
| DISCUSSION
In this randomized trial, faster aspart was shown to be effective in glycaemic control because non-inferiority to IAsp in CSII for the change from baseline in HbA1c after 16 weeks was achieved. Superiority of faster aspart over IAsp in the change in HbA1c, however, was not confirmed, with a small but statistically significant difference in favour of IAsp. Faster aspart significantly improved PPG increment vs IAsp at 30 minutes, 1 hour (superiority confirmed) and 2 hours after a standardized meal test, and this difference was supported by CGM IG postprandial increments and SMBG postprandial increments. These results align well with previous studies 10, 13, 14 ; however, in light of the positive PPG findings in the present trial, it is surprising that faster aspart did not improve HbA1c to a greater extent than IAsp, particularly because a statistically significant difference in favour of faster aspart was demonstrated in a previous study in people with T1D using MDI (onset 1). 10 Contrasting the IG profiles for faster aspart and IAsp, the higher nocturnal and pre-meal levels of IG for participants receiving faster aspart may have countered the expected overall glycaemic benefit of improved PPG control. The reasons underlying this rise in IG are unclear; however, it is likely that both the basal rate and bolus pump settings used for this double-blind trial required further optimization to adjust delivery according to the distinct pharmacological profile of faster aspart. Specific recommendations for the use of faster aspart in CSII may include a different distribution of insulin doses between basal and bolus.
The risk of overall severe or BG-confirmed hypoglycaemia was similar in the two treatment groups; however, the rate of severe or BGconfirmed hypoglycaemia for the small proportion of episodes reported 1 hour after the meal was significantly higher with faster aspart vs IAsp (with no significant differences at other time intervals). This finding was also reported in the onset 1 study after 26 and 52 weeks. The present trial is the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants (with a high participant retention rate) over a clinically meaningful treatment period. With the development of increasingly sophisticated insulin delivery systems comes the need for faster-acting, more physiological insulins that are better able to control PPG fluctuations. The prospective use of ultra-fast-acting insulin in closed-loop therapy is of great clinical interest and studies are underway. [15] [16] [17] [18] In summary, this trial showed that faster aspart provides an effective and safe option for CSII treatment in people with T1D, with improvements in PPG control reflected in meal-test and CGM results.
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